Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Richardson, Paul [1 ]
Hofmeister, Craig [2 ]
Jakubowiak, Andrzej [3 ]
Zimmerman, Todd M. [5 ]
Spear, Matthew A. [4 ]
Palladino, Michael A. [4 ]
Longenecker, Angie M. [4 ]
Kelly, Susan L. [6 ]
Neuteboom, Saskia [7 ]
Cropp, Gillian F. [4 ]
Lloyd, G. Kenneth [4 ]
Hannah, Alison L. [4 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Nereus Pharmaceut Inc, San Diego, CA USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Multiple Myeloma Res Fdn, Norwalk, CT USA
[7] Nereus Pharmaceut Inc, San Diego, CA USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [21] A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando Jose
    Ghermezi, Matthew
    Turner, Carley
    Swift, Regina A.
    Eades, Benjamin M.
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura
    Moss, Robert A.
    Nassir, Youram
    Patel, Ravindranath
    Bessudo, Alberto
    Lim, Stephen
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma
    Spencer, Andrew
    Laubach, Jacob P.
    Zonder, Jeffrey A.
    Badros, Ashraf Z.
    Harrison, Simon
    Khot, Amit
    Chauhan, Dharminder
    Anderson, Kenneth C.
    Reich, Steven D.
    Trikha, Mohit
    Richardson, Paul C.
    BLOOD, 2015, 126 (23)
  • [23] A Phase 1 Trial of Ruxolitinib, Lena-lidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
    Berenson, James
    To, Jennifer
    Spektor, Tanya
    Martinez, Daisy
    Sanchez, Armando
    Ghermezi, Matthew
    Turner, Carley
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura
    Moss, Robert
    Nassir, Youram
    Patel, Ravindranath
    Bessudo, Alberto
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E249
  • [24] Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
    Jayaweera, Shansa Pranami E.
    Wanigasinghe Kanakanamge, Sacheela Prasadi
    Rajalingam, Dharshika
    Silva, Gayathri N.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors
    Kurzrock, R.
    Hamlin, P.
    Gordon, M.
    Hong, D.
    Fu, S.
    Younes, A.
    Hannah, A.
    Palladino, M. A.
    Spear, M. A.
    Aghajanian, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 73 - 74
  • [26] Results from phase 1 dose escalation study of the proteasome inhibitor NPI-0052 in patients with solid tumors and lymphomas
    Kurzrock, Razelle
    Hamlin, Paul
    Younes, Anas
    Hong, David
    Gordon, Michael
    Hannah, Alison
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Longenecker, Angie M.
    Neuteboom, Saskia T. C.
    Cropp, Gillian F.
    Spears, Matthew A.
    Aghajanian, Carol
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3433S - 3433S
  • [27] Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
    Richardson, Paul G.
    Baz, Rachid
    Wang, Michael
    Jakubowiak, Andrzej J.
    Laubach, Jacob P.
    Harvey, R. Donald
    Talpaz, Moshe
    Berg, Deborah
    Liu, Guohui
    Yu, Jiang
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Lonial, Sagar
    BLOOD, 2014, 124 (07) : 1038 - 1046
  • [28] Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma
    Tang, Wenjiao
    Li, Yan
    Liang, Qiushi
    Qu, Ying
    Zhang, Li
    Liu, Yuzhang
    Fang, Baijun
    Yun, Zeng
    Du, Xiaobo
    Xi, Yaming
    Wang, Ting
    Li, Xin
    Huang, Jie
    Qian, Wenbin
    Cai, Zhen
    Zhao, Qingwei
    Lv, Yue
    Niu, Ting
    BLOOD, 2022, 140 : 4396 - 4397
  • [29] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma (MM-014 phase 2 trial): a subanalysis of patients previously treated with lenalidomide and a proteasome inhibitor
    Bahlis, Nizar J.
    Schiller, Gary J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand M.
    Fonseca, Gustavo
    Reece, Donna E.
    Vogel, Prisca
    Lee, Kim
    Chung, Weiyuan
    Agarwal, Amit
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S141 - S141
  • [30] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
    Chari, Ajai
    Larson, Sarah
    Holkova, Beata
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Valent, Jason
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chang, Lipo
    Lee, Yihua
    Pak, Yvonne
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Chhabra, Saurabh
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
12345